tiprankstipranks
Altimmune Inc (GB:0A4C)
LSE:0A4C
UK Market

Altimmune Stock Analysis & Ratings

GB:0A4C Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$5.14
VolumeN/A
Average Volume (3M)895.00
Market Cap$222.16M
P/E RatioN/A
Beta0.51
Next EarningsAug 16, 2022
Dividend YieldN/A
Smart Score7
EPS (TTM)0.00


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:0A4C FAQ

What was Altimmune’s price range in the past 12 months?
Altimmune lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Altimmune’s market cap?
    Altimmune’s market cap is $222.16M.
      What is Altimmune’s price target?
      The average price target for Altimmune is $22.50. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $30.00 ,the lowest forecast is $12.00. The average price target represents 337.74% Increase from the current price of $5.14.
        What do analysts say about Altimmune?
        Altimmune’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
          When is Altimmune’s upcoming earnings report date?
          Altimmune’s upcoming earnings report date is Aug 16, 2022 which is in 90 days.
            How were Altimmune’s earnings last quarter?
            Altimmune released its earnings results on May 12, 2022. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.59 by $0.15.
              Is Altimmune overvalued?
              According to Wall Street analysts Altimmune’s price is currently Undervalued.
                Does Altimmune pay dividends?
                Altimmune pays a Notavailable dividend of $873 which represents an annual dividend yield of N/A. Altimmune’s last Notavailable dividend payment was on Feb 03, 2017. Altimmune’s upcoming ex-dividend date is Feb 06, 2017
                  What is Altimmune’s EPS estimate?
                  Altimmune’s EPS estimate for its next earnings report is not yet available.
                  How many shares outstanding does Altimmune have?
                  Altimmune has 43,220,000 shares outstanding.
                    What happened to Altimmune’s price movement after its last earnings report?
                    Altimmune reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.59. Following the earnings report the stock price went up 0.631%.
                      Which hedge fund is a major shareholder of Altimmune?
                      Among the largest hedge funds holding Altimmune’s share is Ardsley Advisory Partners. It holds Altimmune’s shares valued at 8M.

                        ---

                        Altimmune Stock Analysis

                        The Altimmune stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                        Learn more about TipRanks Smart Score

                        Company Description

                        Altimmune Inc

                        The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.

                        ---
                        Similar Stocks
                        Company
                        Price & Change
                        Follow
                        Emergent Biosolutions
                        Ibio
                        Bavarian Nordic
                        Merck & Company
                        Inovio Pharmaceuticals

                        Popular Stocks

                        ---
                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis